Viridian Therapeutics, Inc./DE Increase (Decrease) in Restricted Cash
Viridian Therapeutics, Inc./DE (VRDN) reported Increase (Decrease) in Restricted Cash of $56 for the 9-month period ending 2014-09-30, per its 10-Q filed 2014-11-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCash · last filed 2014-11-14
- Viridian Therapeutics, Inc./DE increase (decrease) in restricted cash for the quarter ending 2014-09-30 was $37.00, a 48.00% increase year-over-year.
- Viridian Therapeutics, Inc./DE increase (decrease) in restricted cash for the quarter ending 2013-09-30 was $25.00.
| Period end | Increase (Decrease) in Restricted Cash 3 month | Increase (Decrease) in Restricted Cash 6 month | Increase (Decrease) in Restricted Cash 9 month |
|---|---|---|---|
| 2014-09-30 | $37.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | $56.00 10-Q · filed 2014-11-14 | |
| 2014-06-30 | $19.00 10-Q · filed 2014-08-14 | ||
| 2013-09-30 | $25.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | $75.00 10-Q · filed 2014-11-14 | |
| 2013-06-30 | $50.00 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |